Skip to main content

Connect Biopharma Holdings Limited (CNTB)

NASDAQ: CNTB · IEX Real-Time Price · USD
15.00
-1.32 (-8.09%)
After-hours:Oct 22, 2021 6:54 PM EDT
16.32
-1.35 (-7.64%)
At close: Oct 22, 4:00 PM
Market Cap938.13M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out53.94M
EPS (ttm)-8.03
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume224,847
Open17.22
Previous Close17.67
Day's Range15.29 - 17.16
52-Week Range14.02 - 29.27
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 30, 2021

About CNTB

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingos...

IndustryBiotechnology
IPO DateMar 19, 2021
Employees62
Stock ExchangeNASDAQ
Ticker SymbolCNTB
Full Company Profile

Financial Performance

Financial numbers in millions CNYFinancial Statements

News

Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit

SAN DIEGO, CA and TAICANG, SUZHOU, China, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceu...

4 days ago - GlobeNewsWire

Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results

- On Track to Report CBP-201 Phase 2B Top-Line Data Evaluating Moderate-to-Severe Atopic Dermatitis (AD) in Q4 of 2021 -

1 month ago - GlobeNewsWire

Connect Biopharma to Host First Half 2021 Financial Results Conference Call on September 1, 2021

SAN DIEGO and TAICANG, SUZHOU, China, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutica...

1 month ago - GlobeNewsWire

Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member

TAICANG, SUZHOU, China and SAN DIEGO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutica...

2 months ago - GlobeNewsWire

Connect Biopharma to Participate at the Jefferies Virtual Healthcare Conference

SAN DIEGO and TAICANG, SUZHOU, China, May 26, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical...

4 months ago - GlobeNewsWire

Connect Biopharma Announces First Subject Dosed in Phase I Trial Evaluating Safety, Tolerability and Pharmacokinetic ...

Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus

4 months ago - GlobeNewsWire

Connect Biopharma Completes Enrollment of CBP-201 Global Phase 2 Clinical Trial in Moderate-to-Severe Atopic Dermatitis

SAN DIEGO and TAICANG, China, April 08, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical compa...

6 months ago - GlobeNewsWire

Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Connect Biopharma...

NEW YORK--(BUSINESS WIRE)--Deutsche Bank announced today its appointment as depositary bank for the Nasdaq-listed American Depositary Receipt program of Connect Biopharma Holdings Limited. Connect Bioph...

6 months ago - Business Wire

Connect Biopharma Holdings Limited Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Op...

SAN DIEGO and TAICANG, China, March 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (the “Company”), a global clinical-stage biopharmaceutical company dedicated to improvi...

7 months ago - GlobeNewsWire

The IPO Market Had A Busy Week

Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...

7 months ago - Benzinga

Qiming's Portfolio Company Connect Biopharma Lists on Nasdaq

SHANGHAI, March 19, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Connect Biopharma today listed on the Nasdaq with the stock code "CNTB". The issue price is US$ 17.00/ADS.

7 months ago - PRNewsWire

Connect Biopharma Holdings Limited announces pricing of Initial Public Offering

SAN DIEGO and TAICANG, China, March 18, 2021 -- Connect Biopharma Holdings Limited (the “Company”), a global clinical-stage...

7 months ago - GlobeNewswire

Chinese inflammatory disease biotech Connect Biopharma files for a $100 million US IPO

Connect Biopharma Holdings, a Chinese Phase 2 biotech developing therapies for T cell-driven inflammatory diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

7 months ago - NASDAQ

Connect Biopharma Holdings IPO Registration Document (S-1)

Connect Biopharma Holdings Limited has filed to go public with an IPO on the NASDAQ.

7 months ago - SEC